Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 7/20 | 0.57 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12309777 | 0.80 | FDPS (0.66) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL15451137 | 0.80 | FDPS (0.50) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL10073143 | 0.79 | FDPS (0.53) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL14980355 | 0.75 | CYP1A2 (0.57) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL15516269 | 0.74 | CYP1A2 (0.61) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL14036231 | 0.74 | CYP1A2 (0.61) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL7382527 | 0.74 | FDPS (0.54) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL27747578 | 0.74 | NAPRT (0.53) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL8058455 | 0.74 | CYP1A2 (0.56) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL9885374 | 0.73 | FDPS (0.61) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132471-A1 | BISPHOSPHONATE INHALANT FORMULATIONS AND METHODS FOR USING THE SAME | TEIKOKU PHARMA USA, INC. | 2008-06-05 | — | — | US | disclosed |
| US-5869471-A | Methods for the treatment of arthritis using phosphonates and NSAIDS | THE PROCTOR & GAMBLE COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0650361-A1 | COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994000130-A1 | COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132471-A1 | BISPHOSPHONATE INHALANT FORMULATIONS AND METHODS FOR USING THE SAME | BPGM, ENPEP, PTH1R | FDPS 400/4885BTN3A1 791/4885PDE3A 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.